Sanofi treatment of immunoglobulin G4-related disease granted orphan status
US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a ...
Regeneron price target lowered to $1,000 from $1,100 at JPMorgan
JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...